You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Genesis Healthcare (GEN) Outperforming Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Genesis Healthcare (GEN - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Genesis Healthcare is one of 867 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. GEN is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for GEN's full-year earnings has moved 36.11% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that GEN has returned about 4.24% since the start of the calendar year. At the same time, Medical stocks have gained an average of 2.86%. This means that Genesis Healthcare is outperforming the sector as a whole this year.
Looking more specifically, GEN belongs to the Medical - Nursing Homes industry, a group that includes 5 individual stocks and currently sits at #16 in the Zacks Industry Rank. Stocks in this group have gained about 17.17% so far this year, so GEN is slightly underperforming its industry this group in terms of year-to-date returns.
GEN will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.